Table 2.
Mutations and antiviral phenotype of replicons obtained following culturing in the presence of VX-950a using various selection protocols
| Antiviral pressure (fold EC50) | Fold increaseb compared to WT | EC50 ± SDb (μM) | NS3 mutations (aa 1-336)c | Critical phased |
|---|---|---|---|---|
| 1 | 1 | 0.78 ± 0.4 | T22T/I, E176E/G | Y |
| 2 | 3 | 2.0 ± 0.1 | T54T/S, E176E/G, I248I/V, T254T/A, S280S/A | Y |
| 5 | 5 | 3.6 ± 1.4 | T54T/A, A156A/S/T | Y |
| 2-5 | 7 | 5.8 ± 1.0 | T54T/S, V170V/A, E176G, T177T/A, T254A, S280A | Y |
a
EC50, 0.74 ± 0.8 μM; CC50, 24.1 ± 4.4 μM.
b
Data are mean values for ≥2 independent determinations of the antiviral phenotype.
c
Major resistance mutations are indicated in boldface. aa, amino acids.
d
Y, yes; N, no.